Summit Therapeutics SMMT EPS (Basic)
EPS (Basic) at other companies
Other financials
Where this comes from
Reported directly by Summit Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:EarningsPerShareBasic.
The official record: Summit Therapeutics’s 10-Q, filed April 30, 2026, on SEC EDGAR. View the filing →
Ask your AI about Summit Therapeutics's eps (basic).
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Summit Therapeutics's EPS (basic)?
- Summit Therapeutics (SMMT) reported EPS (basic) of -$0.24 in Q1 2026.
- How has Summit Therapeutics's EPS (basic) changed year-over-year?
- Summit Therapeutics's EPS (basic) decreased by 166.7% year-over-year, from -$0.09 to -$0.24.
- What is the long-term trend for Summit Therapeutics's EPS (basic)?
- Over 4 years (2021 to 2025), Summit Therapeutics's EPS (basic) has grown at a 20.6% compound annual growth rate (CAGR), from -$0.68 to -$1.44.
- What does EPS (basic) mean?
- The portion of profit allocated to each share of common stock.
- How do you interpret EPS (basic)?
- Higher values indicate better profitability per share, while negative values indicate a loss per share.
- How does EPS (basic) compare across companies?
- Widely used by investors to compare valuation and earnings power across the industry.